Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VSA006
- Development stage
- Unknown
- Lead developer
- Visirna Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
VSA006 is an investigational small interfering RNA (siRNA) therapeutic developed by Visirna Biotechnology for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). The drug targets the mRNA of hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) in the liver, leading to a reduction in HSD17B13 protein levels. This mechanism is designed to mimic the protective effect of naturally occurring loss-of-function genetic variants of HSD17B13, which are associated with a reduced risk of chronic liver disease progression and cirrhosis. VSA006 is administered via injection and is currently being evaluated in Phase 2 clinical trials to assess its efficacy, safety, and pharmacokinetic profile in patients with NASH.
02
Targets
HSD17B13 (17β-Hydroxysteroid Dehydrogenase Type 13)
Beyond the preview
Go deeper on VSA006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VSA006.